Sign In
Buy SLS
$8.23
-0.81 (-8.96%)
At Close: Jun 05, 2026
Sellas Life Sciences raises $20 million from public offering of stock, warrants
08:42am, Friday, 24'th Feb 2023
Sellas Life Sciences Group Inc. SLS, -3.40% said Friday that it raised $20.0 million, through the public sale of common shares and warrants to buy stock. Shares of the biopharmaceutical company, which
Why Is SELLAS Life Sciences (SLS) Stock Down 38% Today?
08:29am, Friday, 24'th Feb 2023
SELLAS Life Sciences (NASDAQ: SLS ) stock is falling on Friday after the late-stage clinical biopharmaceutical company announced a proposed public offering. According to a press release, SELLAS Life S
NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the developmen
SELLAS Life Sciences Provides Webcast Information for Phase 3 REGAL Study Update on November 14, 2022
08:30am, Wednesday, 02'nd Nov 2022
NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the developme
Solaris and Government of Ecuador Announce Investment Protection Agreement for Warintza Project, Securing Stability of Regulations and Tax Incentives to Accelerate Development
08:05pm, Thursday, 09'th Jun 2022 GlobeNewswire Inc.
VANCOUVER, British Columbia, June 09, 2022 (GLOBE NEWSWIRE) -- Solaris Resources Inc. (TSX: SLS; OTCQB: SLSSF) (“Solaris” or “the Company”) is pleased to announce an agreement with the Gover
SELLAS Life Sciences's Galinpepimut/Opdivo Combo Shows Increased Survival In Mesothelioma Patients
12:11pm, Wednesday, 08'th Jun 2022
SELLAS Life Sciences Group Inc (NASDAQ: SLS) announced updated data from a Phase 1 clinical trial of galinpepimut-S (GPS), combined with Bristol-Myers Squibb Co's (NYSE: BMY) nivolumab (Opdivo) i
SELLAS Life Sciences to Present at the JMP Securities Life Sciences Conference on June 15th
12:30pm, Thursday, 02'nd Jun 2022 GlobeNewswire Inc.
NEW YORK, June 02, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad r
SELLAS Life Sciences to Present at the JMP Securities Life Sciences Conference on June 15th
08:30am, Thursday, 02'nd Jun 2022
NEW YORK, June 02, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad ran
Solaris Receives $30 Million from Warrant Exercises; Fully Funded Through to Mid-2023
11:00am, Friday, 13'th May 2022 GlobeNewswire Inc.
VANCOUVER, B.C., May 13, 2022 (GLOBE NEWSWIRE) -- Solaris Resources Inc. (TSX: SLS; OTCQB: SLSSF) (“Solaris” or the “Company”) is pleased to announce that the Company has received approximat
SELLAS Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update
08:12pm, Thursday, 12'th May 2022 GlobeNewswire Inc.
- Enhanced Pipeline with New Asset, GFH009, an In-licensed Next-Generation, Highly Selective CDK9 Inhibitor -
VANCOUVER, British Columbia, April 18, 2022 (GLOBE NEWSWIRE) -- Solaris Resources Inc. (TSX: SLS; OTCQB: SLSSF) (“Solaris” or the “Company”) is pleased to report an updated mineral resource
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022
02:03pm, Thursday, 14'th Apr 2022 Benzinga
Upgrades
For United Parcel Service Inc (NYSE:UPS), Loop Capital upgraded the previous rating of Hold to Buy. For the fourth quarter, United Parcel Service had an EPS of $3.59, compared to year-ago qua
SELLAS Life Sciences’ Newly Licensed GFH009 Asset Shows Significant Anti-Leukemic Effect in Acute Myeloid Leukemia Patients Relapsed/Refractory to Venetoclax in Ongoing Phase 1 Study
12:15pm, Monday, 11'th Apr 2022 GlobeNewswire Inc.
- Fifth Dose Level Cohort of GFH009, a Highly Selective CDK9 Inhibitor, Initiated -
Solaris Reports 616m of 0.6% CuEq in Additional Drilling at Warintza East, Establishes Continuity of Mineralization with Warintza Central
11:30am, Monday, 11'th Apr 2022 GlobeNewswire Inc.
VANCOUVER, British Columbia, April 11, 2022 (GLOBE NEWSWIRE) -- Solaris Resources Inc. (TSX: SLS; OTCQB: SLSSF) (“Solaris” or “the Company”) is pleased to report assay results from a series
SELLAS Life Sciences Announces Achievement of Development Milestone for Approval of IND for Galinpepimut-S in China
11:00am, Wednesday, 06'th Apr 2022 GlobeNewswire Inc.
SELLAS to Receive $1 Million Milestone Payment in Second Quarter 2022 SELLAS to Receive $1 Million Milestone Payment in Second Quarter 2022
